THANH H. DELLINGER, MD

Associate Chief, Division of Gynecologic Oncology | Associate Professor of Surgery

Division of Gynecologic Oncology, Department of Surgery | City of Hope National Medical Center | Duarte, California, USA

PROFESSIONAL PROFILE

Academic gynecologic oncologist and surgeon-scientist specializing in ovarian, endometrial, and cervical cancers; advanced robotic surgery; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy (HIPEC); and pressurized intraperitoneal aerosolized chemotherapy (PIPAC). Leads clinical trials, translational research, education, and multidisciplinary programs focused on innovative intraperitoneal therapies for gynecologic malignancies.

CURRENT APPOINTMENTS & LEADERSHIP

- Associate Chief, Division of Gynecologic Oncology, Department of Surgery, City of Hope (2026-present).
- Associate Professor, Division of Gynecologic Oncology, Department of Surgery, City of Hope (2021-present).
- Gynecologic Disease Team Co-leader, City of Hope (2021-present).
- Core Teaching Faculty, ACGME Gynecologic Oncology Fellowship (2020-present).
- Leader, U.S. PIPAC Consortium, a multicenter clinical trial network including City of Hope, Mayo Clinic, and Northwell Health (2020-present).

CLINICAL & RESEARCH FOCUS

- Comprehensive surgical care for ovarian, endometrial, and cervical cancers, including advanced robotic laparoscopy and radical cytoreductive surgery.
- Regional treatment strategies for peritoneal malignancies, including HIPEC and PIPAC.
- Translational research in ovarian and endometrial cancer, immunotherapy, tumor biology, pterostilbene, and neural stem cell-delivered oncolytic viro-immunotherapy.

SELECTED RESEARCH & PROGRAM LEADERSHIP

- Site PI, OVHIPEC-2/ENGOT-OV52 Phase III trial evaluating primary cytoreductive surgery with or without HIPEC (2023-present).
- Site PI, GOG3068 HOTT Phase III trial evaluating interval cytoreductive surgery with or without HIPEC Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (HOTT)(2024-present).
- PI, multi-institutional Phase I PIPAC trial for ovarian, uterine, colorectal, and gastric cancers with peritoneal carcinomatosis (2020-present).
- PI, Cherng Family Center preoperative pterostilbene window-of-opportunity trial in endometrial cancer (2025-2026).
- Co-investigator, CIRM study of neural stem cell-delivered oncolytic viro-immunotherapy for ovarian cancer (2024-2026).

EDUCATION & TRAINING

- MD, University of California, Irvine School of Medicine, 2004; BS, Biochemistry/Chemistry, University of California, San Diego, 1999.
- Obstetrics & Gynecology Internship and Residency, Penn State Milton S. Hershey Medical Center (2004-2008).
- Research Fellowship and Clinical Fellowship in Gynecologic Oncology, University of California, Irvine (2008-2012).
- Board certified in Obstetrics and Gynecology (2014) and Gynecologic Oncology (2016).

SCHOLARSHIP & SELECTED CONTRIBUTIONS

- 80 peer-reviewed publications; 7 review articles; 2 editorials and letters; 1 book chapter; and 58 published abstracts.
- Scholarship has advanced HIPEC and PIPAC clinical trials, intraperitoneal therapy, ovarian cancer immunotherapy, and pterostilbene research in endometrial cancer.

SELECTED HONORS & PROFESSIONAL SERVICE

- Cherng Family Center Research Award (2026); GME Excellence in Teaching Award (2026); Top Doctor, Los Angeles (2020-present).
- Editorial Board, Annals of Surgical Oncology (2023-2029); member, American College of Surgeons Cancer Surgery Standards Program Committee (2026-present).
- Course Director, U.S. PIPAC Training Courses; active member of SGO, ASCO, AACR, NRG Oncology, IGCS, ISSPP, and SSO.